BDR Pharma to launch 80mg of Enzalutamide for treatment of Prostate Cancer in India Kumar Jeetendra | September 21, 2020 Mumbai 21st September 2020: BDR Pharmaceutical today announces the launch of 80mg advanced version of its Enzalutamide drug. BDR Pharma had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40mg Enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name BDENZA. The 80 mg …
MRI screening and designated biopsies could diminish overdiagnoses of prostate malignant growth Kumar Jeetendra | July 10, 2021 Many countries do not have nationwide prostate-cancer screening. Current methods lead to overdiagnoses, unnecessary biopsies, and unnecessary biopsies. Researchers at Karolinska Institutet, Sweden, have published a new study in The New England Journal of Medicine. It shows that targeted biopsies and magnetic resonance imaging (MRI), could reduce overdiagnoses by up to half. These results were …
Revolutionizing Medicine: Shape changing RoboCap to deliver drug to cancer cells Kumar Jeetendra | June 14, 2023 Cancer is one of the most devastating medical conditions where unconditional growth of cells takes place and spread to other part of the body, which further leads to various types of cancer including skin cancer, breast cancer, colorectal cancer, pancreatic cancer, prostate cancer and so on. Most prominent approaches to cancer involve chemotherapy and radiation …